Compare AbbVie Inc (ABBV) vs Ishares Msci Brazil ETF (EWZ) Price & Performance

AbbVie (ABBV) trades at $252.63, down 0.84% on the day, with a bullish technical signal and strong support at $248. The stock shows robust fundamentals with revenue growth to $61.16B in 2025 and consistent earnings beats, though net margins have compressed to 5.79%. Recent news highlights positive Phase 2 trial data for ELAHERE in ovarian cancer and institutional accumulation, reinforcing growth prospects beyond Humira's patent expiry.

Outlook remains positive with a consensus price target of $266.33 (5.4% upside), supported by 68% analyst buy ratings. Key opportunities include immunology drugs Skyrizi and Rinvoq driving growth, but risks involve patent cliffs in the 2030s, high debt levels, and regulatory pressures on drug pricing. The stock offers a resilient dividend with recent increases, appealing for income-focused investors amid sector volatility.

EWZ, the iShares MSCI Brazil ETF, trades at $34.92, up 1.42% over 24 hours, with a bullish technical signal driven by moving averages. The ETF has gained approximately 11% year-to-date, supported by Brazil's monetary easing cycle and commodity strength. Recent news highlights potential as a 2026 sleeper trade if rate cuts proceed, with exposure to Brazilian equities trading at a forward P/E of 9.6x as of Seeking Alpha on 2026-05-05.

Outlook is positive due to asymmetric upside from rate cuts, election repricing, and commodity tailwinds, but risks include Brazil's economic volatility and dependency on Petrobras/Vale dividends. Investors face currency and political uncertainties, though institutional interest remains with new positions like Altfest's $4.72 million investment in Q4 2025 per Defense World on 2026-04-12.